Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

Vaccine

Volumn 31, Issue 9, 2013, Pages 1340-1348

  Grode, Leander ^a   Ganoza, Christian A ^b   Brohm, Christiane ^a   Weiner, January ^b   Eisele, Bernd ^a   Kaufmann, Stefan H E ^b  

^a Vakzine Projekt Management GmbH   (Belgium)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

BCG; Clinical trial; Immune response; Safety; Tuberculosis; Vaccination

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; GAMMA INTERFERON; RECOMBINANT VACCINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LABORATORY TEST; LUNG TUBERCULOSIS; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION; VOLUNTEER;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BCG VACCINE; FLOW CYTOMETRY; HUMAN EXPERIMENTATION; HUMANS; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84873446135     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.053     Document Type: Article

References (42)

1. WHO Global tuberculosis report 2012 2012, WHO Press, Geneva.
2. WHO Global tuberculosis control 2011 2011, World Health Organization, Geneva.
3. Lonnroth K., Castro K.G., Chakaya J.M., Chauhan L.S., Floyd K., Glaziou P., et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010, 375(May (9728)):1814-1829.
4. Steingart K.R., Ng V., Henry M., Hopewell P.C., Ramsay A., Cunningham J., et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006, 6(October (10)):664-674.
5. Wallis R.S., Pai M., Menzies D., Doherty T.M., Walzl G., Perkins M.D., et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375(May (9729)):1920-1937.
6. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54(February (4)):579-581.
7. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011, 11(August (8)):633-640.
8. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25(January (1)):14-18.
9. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009, 106(August (33)):13980-13985.
10. Geoffroy C., Gaillard J.L., Alouf J.E., Berche P. Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect Immun 1987, 55(July (7)):1641-1646.
11. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005, 115(9):2472-2479.
12. Farinacci M., Weber S., Kaufmann S.H.E. The recombinant tuberculosis vaccine rBCG ΔureC::hly+ induces apoptotic vescicles for improved priming of CD4+ and CD8+ T cells. Vaccine 2012, 10.1016/j.vaccine.2012.10.031.
13. Bavdek A., Kostanjsek R., Antonini V., Lakey J.H., Dalla S.M., Gilbert R.J., et al. pH dependence of listeriolysin O aggregation and pore-forming ability. FEBS J 2012, 279(January (1)):126-141.
14. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290(November (5493)):992-995.
15. Schnupf P., Portnoy D.A., Decatur A.L. Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell Microbiol 2006, 8(February (2)):353-364.
16. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204(September (10)):1573-1584.
17. World Medical Association. Declaration of Helsinki (revised 2008); 1964.
18. WHO. Expert Committee on Biological Standardization: Recommendations to assure the quality, safety and efficacy of BCG vaccines. http://www%20who%20int/biologicals/BCG_DB_HK_23_April_2012%20pdf%202011.
19. Pinheiro J.C., Bates D.M. Mixed-effects models in S and S-PLUS 2000, Springer, New York.
20. Casadevall A., Pirofski L.A. A new synthesis for antibody-mediated immunity. Nat Immunol 2012, 13(January (1)):21-28.
21. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334(December (6062)):1488-1490.
22. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27(July (33)):4412-4423.
23. Jung Y.J., Ryan L., Lacourse R., North R.J. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2005, 201(June (12)):1915-1924.
24. Zhang S.Y., Boisson-Dupuis S., Chapgier A., Yang K., Bustamante J., Puel A., et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008, 226(December):29-40.
25. Kim B.H., Shenoy A.R., Kumar P., Das R., Tiwari S., MacMicking J.D. A family of IFN-gamma-inducible 65-kD GTPases protects against bacterial infection. Science 2011, 332(May (6030)):717-721.
26. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37(January (1)):88-99.
27. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
28. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(July (7)):843-850.
29. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81(August (16)):8468-8476.
30. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006, 6(May (5)):417-423.
31. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
32. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
33. Fillatreau S. Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection. Immunol Rev 2011, 240(March (1)):52-71.
34. Joller N., Weber S.S., Oxenius A. Antibody-Fc receptor interactions in protection against intracellular pathogens. Eur J Immunol 2011, 41(April (4)):889-897.
35. Maglione P.J., Xu J., Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007, 178(June (11)):7222-7234.
36. Maglione P.J., Xu J., Casadevall A., Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008, 180(March (5)):3329-3338.
37. Sander L.E., Davis M.J., Boekschoten M.V., Amsen D., Dascher C.C., Ryffel B., et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011, 474(June (7351)):385-389.
38. Blander J.M., Sander L.E. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol 2012, 12(March (3)):215-225.
39. Aaby P., Roth A., Ravn H., Napirna B.M., Rodrigues A., Lisse I.M., et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. J Infect Dis 2011, 204(June (2)):245-252.
40. Roth A., Garly M.L., Jensen H., Nielsen J., Aaby P. Bacillus Calmette-Guerin vaccination and infant mortality. Expert Rev Vaccines 2006, 5(April (2)):277-293.
41. Garly M.L., Martins C.L., Bale C., Balde M.A., Hedegaard K.L., Gustafson P., et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?. Vaccine 2003, 21(June (21-22)):2782-2790.
42. Kaufmann S.H., Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012, 23(April):900-907.